ABAnna Bäck

Anna Bäck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Bäck has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Vaniqui

    Belgian Nuclear Research Center (SCK CEN), Mol, Belgium

    1 shared publication
  • Andreas Hallqvist

    Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

    1 shared publication
  • Christian Rønn Hansen

    Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication
  • Jan Nyman

    Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden

    1 shared publication
  • Kerstin Gunnarsson

    Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden

    1 shared publication
  • Lamberto Widesott

    Centro di Protonterapia, APSS, Trento, Italy

    1 shared publication

Latest Publications

  • Open Access

    Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

    by Kerstin Gunnarsson, Louise Mövik, Niclas Pettersson, Anna Bäck, Jan Nyman, Andreas Hallqvist

    Purpose: Radiation pneumonitis (RP) is a dose-limiting toxicity associated with increased mortality for patients with non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT). This study aims to assess the incidence of symptomatic RP (grade 2–5), rate of recovery and associated predictive factors. Material and methods: We performed a retrospective population-based study including 602 patients with NSCLC who were treated with CRT between 2002 and 2016. RP and rate of recovery were analysed using Common Terminology Criteria for Adverse Events version 4.0. Stepwise logistic regression was performed to analyse potential predictive factors for the two endpoints RP grade ≥ 2 and RP grade ≥ 3. Results: A total of 136 (23%) patients developed symptomatic RP and 37 (6%) developed RP grade ≥ 3. A total of 67 (71%) recovered, whereas the remaining 27 (29%), with the major proportion of patients belonging to the RP grade ≥ 3 group, suffered from prevailing sequelae. On multivariable analysis, the selected model for predicting RP grade ≥ 2 included the factors V20, smoking status, average fractions per week and chemotherapy agent. V20 and age were selected factors for RP grade ≥ 3. Interpretation: The results suggest that regardless of all proposed factors predictive for RP, the most important influenceable significant factor still is dose to the lung. The main aim should be to avoid RP grade ≥ 3, where a substantial proportion of patients suffer from prevailing sequalae. Consequently, the technical improvement and precision of radiotherapy delivery should continue to focus on lung sparing techniques also in the ongoing immunotherapy-containing schedules where the risk of pneumonitis may be increased. e factor still is dose to the lung. Consequently, the technical improvement and precision of radiotherapy delivery should continue to focus on lung sparing techniques also in the ongoing immunotherapy-containing schedules where the risk of pneumonitis may be increased.


  • Open Access

    Plan quality assessment in clinical practice: Results of the 2020 ESTRO survey on plan complexity and robustness

    by Laura Patricia Kaplan, Lorenzo Placidi, Anna Bäck, Richard Canters, Mohammad Hussein, Ana Vaniqui, Marco Fusella, Tomasz Piotrowski, Victor Hernandez, Nuria Jornet, et al.